The Food and Drug Administration proposed a rule to find that N-acetyl-L-cysteine, or NAC, is not excluded from the definition of a dietary supplement under the Federal Food, Drug, and Cosmetic Act, according to the notice published Tuesday. The proposed rule says that, if finalized, products containing NAC could be lawfully marketed as dietary supplements if they comply with all other provisions of the law. The proposal also would specify that adding NAC to a dietary supplement would not be an offense under section 301(ll) of the act.

FDA said it plans to create a new regulation at 21 CFR 190.1 to list dietary ingredients not excluded from the dietary supplement definition, with NAC as the first listed ingredient. The agency said it is acting under three provisions of the FD&C Act: 201(ff)(3)(B), 301(ll)(2), and 701(a). The Federal Register notice states the proposed rule was signed by President Donald Trump.

FDA explained that NAC is a dietary ingredient but has been excluded from the dietary supplement definition because it received approval as a new drug before any marketing as a dietary supplement or a food. The agency said it has exercised temporary enforcement discretion since August 2022 for certain NAC products labeled as dietary supplements while it considered rulemaking. If the rule is finalized, FDA said it intends to withdraw that enforcement discretion guidance.

FDA said its safety assessment focused on orally administered NAC and used a systematic review of 41 high-confidence studies. The agency reported a “minimal” level of concern for adverse events, noting most studies showed no increase in adverse events compared with controls. Reported effects were mainly non-serious gastrointestinal symptoms, such as nausea, vomiting, and abdominal discomfort, with one study showing a significant increase in nausea. FDA said study doses, up to 9,000 milligrams per day and durations up to three years, overlapped with recommended servings on NAC products labeled as dietary supplements.

On drug development, FDA said allowing NAC in dietary supplements is likely to have minimal, if any, impact. The notice recounted NAC’s drug approvals and said NAC has been continuously approved as a drug since 1963. The agency said it is using its rulemaking authority to ensure adequate safeguards if regulated as a dietary supplement and to avoid undermining incentives for drug development.

FDA estimated industry costs for reading and understanding a final rule would be small. The agency’s primary annualized cost estimates are about $99 at a 3 percent discount rate and $121 at a 7 percent rate, with a present value of about $848.

Comments on the proposed rule are due by Jan. 19, 2027. FDA said comments may be submitted electronically at regulations.gov until 11:59 p.m. Eastern Time on that date, or by mail or hand delivery to the Dockets Management Staff in Rockville, Md., under Docket No. FDA-2025-N-2699. The agency did not give an effective date; the proposal would not take effect unless finalized.